Indian stocks: Visit www.stage2stocks.com →

abrdn Life Sciences Investors

Stage 3 · Topping · week 3

As of Oct 22, 2026, abrdn Life Sciences Investors is in Stage 3, the topping phase, now in week 3 (since Oct 6, 2026). It closed at $17.95, 18.6% below its 52-week high and above its 200-day average, which is rising.

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. More about the company

$17.95
+0.17% today
$546M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is HQL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 18w
S2 24w
S4 18w
S2 62w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 18w → S1 3w → S2 12w → S3 7w → S2 24w → S3 12w → S4 18w → S1 6w → S2 62w → S3 2w current
Total tracked: 165 weeks across 10 stage runs.

HQL among Asset Management19th of 140 by relative strength

All 140 →
Stocks in Asset Management ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CYPHStage 2 · wk 799−17.5%
2AMTDStage 2 · wk 199+4011.1%
3MGLDStage 2 · wk 494+105.2%
4AAMIStage 2 · wk 4194+1.4%
5ASSTStage 2 · wk 792+0.1%
6AMGStage 2 · wk 2191+8.0%
7WTStage 2 · wk 3991−10.6%
8VCTRStage 2 · wk 3991+1.0%
…19HQLStage 3 · wk 370−8.2%
vs 52W High
-18.6%
$14.08 lo$22.04 hi
18.6% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 3
1w13w26w
Week 3, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
2.6%
200 DMA: $17.49 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.88x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-8.2%
3M
-4.1%
6M
+9.5%
YTD
+17.5%
1Y
+20.7%
Scan Membership
Breakout Watch
Latest: 2024-06-03
9 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 3 · Vol 0.88x
2026-10-21S3
Wk 3 · Vol 0.64x
2026-10-20S3
Wk 3 · Vol 0.72x
2026-10-19S3
Wk 2 · Vol 1.11x
2026-10-16S3
Wk 2 · Vol 0.88x
2026-10-15S3
Wk 2 · Vol 0.73x
2026-10-14S3
Wk 2 · Vol 1.13x
2026-10-13S3
Wk 2 · Vol 1.19x
2026-10-12S3
Wk 1 · Vol 0.62x
2026-10-09S3
Wk 1 · Vol 0.74x
2026-10-08S3
Wk 1 · Vol 0.76x
2026-10-07S3
Wk 1 · Vol 0.64x
Moving averages & range
50 DMA
$19.45
200 DMA
$17.49
52W High
$22.04
52W Low
$14.08
5D Low
$16.78
Resistance levels (recent highs)
20d High
$18.97
60d High
$22.04
120d High
$22.04
250d High
$22.04
Next resistance
+5.7%
to 20d High
P/E (TTM)
2.7
Forward —
ROE
+41.4%
Profit margin +17857.0%
Dividend Yield
12.50%
P/B 1.0

abrdn Life Sciences Investors: quick answers

What stage is abrdn Life Sciences Investors in?

As of Oct 22, 2026, abrdn Life Sciences Investors (HQL) is in Stage 3, the topping phase. It entered Stage 3 on Oct 6, 2026 and is in week 3. What the four stages mean

Is abrdn Life Sciences Investors in an uptrend?

Its uptrend has stalled. abrdn Life Sciences Investors is in Stage 3, the topping phase that follows an advance. It trades 2.6% above its 200-day average, which is rising.

How far is abrdn Life Sciences Investors from its 52-week high?

abrdn Life Sciences Investors closed at $17.95 on Oct 22, 2026, 18.6% below its 52-week high of $22.04. Its 52-week low is $14.08.

How has abrdn Life Sciences Investors performed over the past year?

As of Oct 22, 2026, abrdn Life Sciences Investors is up 20.7% over the past year and up 17.5% so far in 2026.

Which sector and industry is abrdn Life Sciences Investors in?

abrdn Life Sciences Investors is in the Asset Management industry, part of the Financials sector.

About this companyFinancials· Asset Management

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.